Grania Brigden: Mind the deadly gaps in the TB response

The 45th Union World Conference on Lung Health, recently held in Barcelona, opened with the health ministers of South Africa and India making bold commitments to address and reverse the tuberculosis epidemics in their countries. Five other countries also committed to ending TB, resulting in the birth of the Barcelona Declaration on TB. This political commitment […]

Read More…

The price of joining the middle income country club: reduced access to medical innovation

When people think about medical humanitarian aid, the usual association is with war zones and natural disasters, and the assumption is that the most critical medical needs are concentrated in the world’s poorest countries. That’s mostly right, but not entirely. While the needs of low income countries remain huge, there are large—and growing—populations excluded from […]

Read More…

MSF Scientific Day 2014: The role of evidence in humanitarian aid

This year marks the 20th anniversary of the Rwandan genocide, in which between 500 000 and a million people were brutally killed. The international community failed to act and MSF concluded that “you can’t stop genocide with doctors.” The aftermath of the genocide included analysis of the failures of humanitarian aid, and led to moves […]

Read More…

Goodman Makhanda and Jennifer Hughes: Drug resistant TB—dying for better treatment

Two weeks ago there was a small celebration in a primary care clinic in Khayelitsha, South Africa. Siyabulela Qwaka* was officially declared cured after taking more than two years of treatment for pre-XDR TB (extensively drug resistant tuberculosis). This is hugely significant given that the chance of cure for someone with pre-XDR or XDR TB is […]

Read More…

Manica Balasegaram: Drugs for the poor, drugs for the rich—why the current research and development model doesn’t deliver

The past month has seen the reputation of “Big Pharma” dented more than usual. The CEO of German pharmaceutical company Bayer, Marijn Dekkers, was reported as saying that the company didn’t develop a cancer drug for the Indian market, but rather “for Western patients who can afford it.” The comment summed up the attitude of […]

Read More…